Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. more
Time Frame | APLS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.9% | -2.28% | -0.57% |
1-Month Return | 17.49% | -3.98% | 1.2% |
3-Month Return | -11.78% | -9.71% | 7.56% |
6-Month Return | -22.02% | -3.39% | 11.44% |
1-Year Return | -47.22% | 3.69% | 28.47% |
3-Year Return | -23.17% | 3.78% | 29.51% |
5-Year Return | 19.91% | 39.76% | 90.64% |
10-Year Return | 136.56% | 106.88% | 203.73% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 250.65M | 66.56M | 75.42M | 396.59M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":63.2,"profit":true},{"date":"2021-12-31","value":16.78,"profit":true},{"date":"2022-12-31","value":19.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 288.02M | 25.05M | 5.20M | 5.64M | 58.51M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":8.7,"profit":true},{"date":"2021-12-31","value":1.81,"profit":true},{"date":"2022-12-31","value":1.96,"profit":true},{"date":"2023-12-31","value":20.31,"profit":true}] |
Gross Profit | (288.02M) | 225.60M | 61.36M | 69.79M | 338.08M | [{"date":"2019-12-31","value":-85.19,"profit":false},{"date":"2020-12-31","value":66.73,"profit":true},{"date":"2021-12-31","value":18.15,"profit":true},{"date":"2022-12-31","value":20.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | 90.01% | 92.19% | 92.53% | 85.25% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":97.27,"profit":true},{"date":"2021-12-31","value":99.63,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.13,"profit":true}] |
Operating Expenses | 288.02M | 439.32M | 597.64M | 664.40M | 855.20M | [{"date":"2019-12-31","value":33.68,"profit":true},{"date":"2020-12-31","value":51.37,"profit":true},{"date":"2021-12-31","value":69.88,"profit":true},{"date":"2022-12-31","value":77.69,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (288.02M) | (213.73M) | (536.28M) | (594.61M) | (517.12M) | [{"date":"2019-12-31","value":-28801525300,"profit":false},{"date":"2020-12-31","value":-21372600000,"profit":false},{"date":"2021-12-31","value":-53627700000,"profit":false},{"date":"2022-12-31","value":-59461300000,"profit":false},{"date":"2023-12-31","value":-51712100000,"profit":false}] |
Total Non-Operating Income/Expense | (16.87M) | (155.08M) | (222.55M) | (80.60M) | (18.02M) | [{"date":"2019-12-31","value":-1686719100,"profit":false},{"date":"2020-12-31","value":-15507600000,"profit":false},{"date":"2021-12-31","value":-22254800000,"profit":false},{"date":"2022-12-31","value":-8060200000,"profit":false},{"date":"2023-12-31","value":-1802300000,"profit":false}] |
Pre-Tax Income | (304.71M) | (343.03M) | (746.00M) | (651.50M) | (526.50M) | [{"date":"2019-12-31","value":-30470661300,"profit":false},{"date":"2020-12-31","value":-34302900000,"profit":false},{"date":"2021-12-31","value":-74600200000,"profit":false},{"date":"2022-12-31","value":-65150300000,"profit":false},{"date":"2023-12-31","value":-52649600000,"profit":false}] |
Income Taxes | 5.11M | 1.84M | 352.00K | 669.00K | 2.13M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":36.11,"profit":true},{"date":"2021-12-31","value":6.89,"profit":true},{"date":"2022-12-31","value":13.09,"profit":true},{"date":"2023-12-31","value":41.73,"profit":true}] |
Income After Taxes | (309.82M) | (344.87M) | (746.35M) | (652.17M) | (528.63M) | [{"date":"2019-12-31","value":-30981590900,"profit":false},{"date":"2020-12-31","value":-34487400000,"profit":false},{"date":"2021-12-31","value":-74635400000,"profit":false},{"date":"2022-12-31","value":-65217200000,"profit":false},{"date":"2023-12-31","value":-52862800000,"profit":false}] |
Income From Continuous Operations | (304.71M) | (344.87M) | (746.35M) | (652.17M) | (528.63M) | [{"date":"2019-12-31","value":-30470661300,"profit":false},{"date":"2020-12-31","value":-34487400000,"profit":false},{"date":"2021-12-31","value":-74635400000,"profit":false},{"date":"2022-12-31","value":-65217200000,"profit":false},{"date":"2023-12-31","value":-52862800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (309.82M) | (344.87M) | (746.35M) | (652.17M) | (528.63M) | [{"date":"2019-12-31","value":-30981590900,"profit":false},{"date":"2020-12-31","value":-34487400000,"profit":false},{"date":"2021-12-31","value":-74635400000,"profit":false},{"date":"2022-12-31","value":-65217200000,"profit":false},{"date":"2023-12-31","value":-52862800000,"profit":false}] |
EPS (Diluted) | (4.86) | (4.72) | (8.93) | (6.13) | (4.48) | [{"date":"2019-12-31","value":-486,"profit":false},{"date":"2020-12-31","value":-472,"profit":false},{"date":"2021-12-31","value":-893,"profit":false},{"date":"2022-12-31","value":-613,"profit":false},{"date":"2023-12-31","value":-448,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
APLS | |
---|---|
Cash Ratio | 2.07 |
Current Ratio | 4.36 |
Quick Ratio | 3.73 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
APLS | |
---|---|
ROA (LTM) | -16.23% |
ROE (LTM) | -106.56% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
APLS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.74 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.26 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
APLS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5.99 |
P/B | 17.18 |
Price/FCF | 126 |
EV/R | 5.80 |
EV/Ebitda | NM |
Apellis Pharmaceuticals Inc (APLS) share price today is $33.699
Yes, Indians can buy shares of Apellis Pharmaceuticals Inc (APLS) on Vested. To buy Apellis Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in APLS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Apellis Pharmaceuticals Inc (APLS) via the Vested app. You can start investing in Apellis Pharmaceuticals Inc (APLS) with a minimum investment of $1.
You can invest in shares of Apellis Pharmaceuticals Inc (APLS) via Vested in three simple steps:
The 52-week high price of Apellis Pharmaceuticals Inc (APLS) is $73.8. The 52-week low price of Apellis Pharmaceuticals Inc (APLS) is $24.34.
The price-to-earnings (P/E) ratio of Apellis Pharmaceuticals Inc (APLS) is
The price-to-book (P/B) ratio of Apellis Pharmaceuticals Inc (APLS) is 17.18
The dividend yield of Apellis Pharmaceuticals Inc (APLS) is 0.00%
The market capitalization of Apellis Pharmaceuticals Inc (APLS) is $4.29B
The stock symbol (or ticker) of Apellis Pharmaceuticals Inc is APLS